Table 2.
MR with clinical impact according to MERP index (n = 2289)
| MERP Classification* | n (%) | Example treatment policy adjustment |
|---|---|---|
| C | 40 (1.7%) |
Discontinuation OTC medication: glucosamine/chondroitin Requesting lab work |
| D | 14 (0.6%) |
Increasing candesartan dosage as dose in the EHR was incorrect Ordering a DEXA scan |
| E | 15 (0.7%) |
Discontinuation of prescribed medication: apixaban, metoclopramide Adjustment of a medical procedure (using a smaller needle) due to clopidogrel usage |
| F | 5 (0.2%) | Not prescribing carbamazepine based on interaction with apixaban (another anti-epileptic was chosen). |
| G | 3 (0.1%) | Starting medication: bisphosphonate for a patient at high risk |
| H | 2 (0.1%) | Replacing of oral miconazole with nystatin based on an interaction with a coumarin |
| I | 1 (0.04%) | Starting insulin (The patient, contrary to what the physician believes, was not using insulin) |
| Not classified | 8 (0.3%) | |
| All | 88 (3.8%) |
*Options A and B do not occur due to the study design; by definition, the error has reached the patient because the physician had already established treatment policy at the time of MERP classification.